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OBJECTIVES: To examine the association between extended-
release, once-daily morphine sulfate (Avinza®, A-MSER) and
cognitive function (CF) while controlling for pain intensity (PI),
pain-related emotions (PE), pain-related behaviors (PB), and ben-
zodiazepine dose (BD). METHODS: Chronic non-malignant
pain patients whose pain was not adequately controlled with
short-acting narcotic analgesics and eligible for treatment with
A-MSER were enrolled. Patients completed the following assess-
ments at baseline and 4 weeks after stabilization of the A-MSER
dose: PI, PE, PB and CF tests measuring short-term memory
(digit span test—DST), information processing (paced auditory
serial addition test—PASAT), and motor skills (digit symbol
test—DSYT). Self-reports of average narcotic dose and BD in the
week prior to the assessment were recorded at baseline and
follow-up. Three structural equation models were developed;
each CF test serving as the dependent variable and other assess-
ments serving as predictor variables. RESULTS: Paired sample t-
tests showed statistically signiﬁcant (p < 0.05) improvements in
PI, PE, PB, and CF test scores. Chi-square ﬁt statistics showed
that the three models with DST (chi-square = 147.79, p = 0.76),
DSYT (chi-square = 128.06, p = 0.5), and PASAT (chi-square =
160.39, p = 0.85) ﬁt the data well. In each model, the associa-
tion between narcotic dose and CF test scores was not statisti-
cally signiﬁcant (p > 0.05) at baseline and follow-up. A
statistically signiﬁcant (p < 0.05) inverse association between BD
(1% dose increase) and DSYT scores (0.05% decline) and
PASAT scores (0.06% decline) were observed at baseline; the
direction of the association persisted but was not signiﬁcant at
follow-up. CONCLUSION: Narcotic therapy does not con-
tribute to cognitive impairment in this sample of chronic pain
patients, however, evidence of an inverse dose-dependent associ-
ation between BD and tests assessing information processing and
motor skills was observed.
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OBJECTIVES: Strong opioids are widely used for many chronic
pain conditions. In a Danish nationwide register-based case-
control study an increased risk for osteoporotic fractures was
shown for opioid users and explained by falls due to central
nervous system side effects, such as dizziness. Odds ratios were
calculated for osteoporotic patients on treatment for at least 10
days with tramadol, morphine, fentanyl, oxycodone, and
buprenorphine, being lowest with buprenorphine. The purpose
of this study was to evaluate the costs related with an increased
risk of hip, forearm or spine fractures in patients on tramadol,
morphine, fentanyl, oxycodone, and buprenorphine treatment in
Germany. METHODS: Treatment costs for fractures were
obtained from published sources for the year 2006, including
direct costs within the ﬁrst year after fracture, i.e. in- and out-
patient treatment, rehabilitation and long-term care (the latter
only for social security perspective). Information on patients
with osteoporosis in Germany was derived from published data.
Perspectives were those from German social security (GSS) and
statutory health insurance (SHI). RESULTS: Mean costs per
patient due to the treatment of fractures from the GSS/SHI 
perspective were €833/€430 for tramadol, €408/€214 for mor-
phine, €645/€341 for fentanyl, €465/€242 for oxycodone, and
€307/€171 for buprenorphine, respectively. Taking into consid-
eration the estimated number of patients with osteoporosis
treated with tramadol, morphine, fentanyl or oxycodone of 2.6
million in Germany, additional annual costs for the treatment of
fractures that could be saved with buprenorphine were calcu-
lated to €1.0 and €0.5 billion (GSS and SHI, respectively). Sen-
sitivity analyses on costs and fracture rates showed the
robustness of model’s results. CONCLUSION: An increased
fracture risk associated with tramadol, morphine, fentanyl and
oxycodone results in a considerable economic burden for the
social system which can be reduced by using opioids associated
with lower fracture risks, such as buprenorphine.
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OBJECTIVES: Since the Palliative Care Service started at MD
Anderson Cancer Center in 1999, there has been an increased
usage of methadone within the institution. This study was
designed to assess the effect of increased methadone usage on the
overall cost of opioid utilization. METHODS: We evaluated the
inpatient usage patterns for methadone (oral, SQ, and IV), trans-
dermal fentanyl (TDF), and sustained release oxycodone (SRO)
and morphine (SRM). Using the pharmacy database, for the
month of October in each year from 1999–2004, the following
data was collected: total milligrams used per day by product,
conversion to morphine equivalent daily dose (MEDD) used by
product, average wholesale price (AWP), number of unique
patients by product, total days of product use, and total number
of inpatient days (INPD). A total of 12,625 unique drug doses
were included in the ﬁnal database. RESULTS: The number of
unique patients receiving opioids increased for all study drugs.
The usage of methadone in MEDD increased 400% from 1999
to 2004. Using AWP per patient day treated, TDF was $9.43,
SRO was $3.63, methadone was $2.38, and SRM was $1.24. In
total usage, methadone provided the largest MEDD (mg/day)
coverage, up to 9 times the amount of TDF. Since 2000,
methadone has contributed more MEDD as a percentage than
the other 3 agents combined, while the methadone MEDD cost
contribution has never been more than 10%. The mean for the
cost of 1 mg of MEDD per patient day was $0.02 for methadone,
$0.02 for SRO, $0.11 for SRM, and $0.216 for TDF. CON-
CLUSION: Usage of methadone has increased. The MEDD con-
tribution of methadone surpasses other long acting opioids in
our inpatient population. The non-annualized total cost per
MEDD mg for all products combined has remained stable at
$0.05, but cost per patient treated increased by $0.77 per
(INPD). Analysis continues.
